Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsFRA:9BK0 +2.73%54 5-Year Yield-on-Cost % is 5.00 as of Aug. 14, 2026, which is 199% above its 10-year median of 1.67. GuruFocus rates FRA:9BK0 with a GF Score™ of 54/100 and a GF Value™ of €7.57 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 275 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 69.82% on this metric.
ABL Diagnostics's yield on cost for the quarter that ended in Dec. 2025 was 5.00.
The historical rank and industry rank for ABL Diagnostics's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:9BK0'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.3 Med: 1.67 Max: 5.09
Current: 5
During the past 13 years, ABL Diagnostics's highest Yield on Cost was 5.09. The lowest was 1.30. And the median was 1.67.
FRA:9BK0's 5-Year Yield-on-Cost % is ranked better than 69.82% of 275
companies
in the Healthcare Providers & Services industry
Industry Median: 2.94
vs FRA:9BK0: 5.00
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
ABL Diagnostics 5-Year Yield-on-Cost % Related Terms
FRA:9BK0 vs VEEV, BTSG, HQY: 5-Year Yield-on-Cost % Comparison
For the Health Information Services subindustry, ABL Diagnostics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of ABL Diagnostics is calculated as
ABL Diagnostics (FRA:9BK0) has a 5-Year Yield-on-Cost % of 5.00 as of Aug. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ABL Diagnostics and its competitors. This is 199% above median its historical median of 1.67. Over the past decade, ABL Diagnostics' 5-Year Yield-on-Cost % has ranged from 1.30 to 5.09. According to the industry distribution chart, ABL Diagnostics ranks #83 out of 275 companies in the Healthcare Providers & Services industry, placing it in the top 30.2%.
Is ABL Diagnostics' 5-Year Yield-on-Cost % too high?
ABL Diagnostics' current 5-Year Yield-on-Cost % of 5.00 is 199% above median its 10-year median of 1.67. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 5.09. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.94. ABL Diagnostics' value of 5.00 is 70.1% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #83 out of 275 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #83 out of 275 companies for 5-Year Yield-on-Cost %. This puts ABL Diagnostics in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.94. ABL Diagnostics' value of 5.00 is 70.1% above this benchmark. Historically, ABL Diagnostics' own 5-Year Yield-on-Cost % has ranged from 1.30 to 5.09 over the past decade. While the company's 10-year median is 1.67 vs. the industry median of 2.94, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.94, based on 275 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current 5-Year Yield-on-Cost % of 5.00 is 70.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current 5-Year Yield-on-Cost % is 5.00, which is 199% above median its own 10-year median of 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (FRA:9BK0) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.57, compared to a current price of €2.26 — trading 70.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.00, which is 199% above median its 10-year median of 1.67 and 70.1% above the Healthcare Providers & Services industry median of 2.94. ABL Diagnostics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For ABL Diagnostics (FRA:9BK0), the current 5-Year Yield-on-Cost % is 5.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (FRA:9BK0) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.26 is trading 70.1% below its estimated GF Value™ of €7.57.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for FRA:9BK0:
5-Year Yield-on-Cost %: 5.00 (199% above median its 10-year median of 1.67)
GF Value™: €7.57 vs. price of €2.26 (70.1% below fair value)
Industry Position: 70.1% above the Healthcare Providers & Services median (#83 of 275)
No single metric tells the full story. See the FRA:9BK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
54GF Score
Get the complete analysis for FRA:9BK0
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9BK0 has been successfully added to your 
